Insights Into HR+, HER2– Metastatic Breast Cancer (mBC)

Expert analysis of HR+, HER2– metastatic breast cancer, featuring new developments in oral SERDs and PROTAC therapies and their potential influence on future treatment approaches.

December 22, 2025
Purchase Report

Faculty Chair

Seth Wander, MD, PhD

Harvard University, Cambridge, MA, USA

More Information

  • Virtual series
  • Florida, Georgia, Michigan, Maryland

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • Explore current HR+, HER2– mBC treatment practices and the latest clinical updates
  • Assess new data and differentiating factors for oral SERDs and PROTAC therapies in HR+, HER2– mBC
  • Consider the impact of oral SERDs and PROTAC therapies on future treatment approaches, including anticipated challenges and unmet needs

GEOGRAPHIC REPRESENTATION AND CONTENT DEVELOPMENT

  • Data collection was accomplished through the use of audience response system questioning and moderated discussion
  • The group of experts comprised 12 community oncologists from the Eastern region of the United States

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.